Takara Bio Inc. (4974)

Overview

Takara Bio Inc., established in 2002 and headquartered in Kusatsu, Japan, operates across the globe including in Japan, China, the rest of Asia, the United States, and Europe. As a key player in the bioindustry, Takara Bio Inc. involves itself in diverse sectors such as bioindustry, contract development and manufacturing organization (CDMO), and gene therapy. The company stands as a significant subsidiary of Takara Holdings Inc., expanding its technological frontier in biologics development, particularly in the gene therapy arena. Through its comprehensive suite of products and services, Takara Bio Inc. addresses the needs of genetic research, clinical diagnostics, and regenerative medicine, showcasing its commitment to advancing healthcare and scientific understanding.

Products and Services

Takara Bio Inc. offers an extensive array of products and services catered to various scientific and medical needs:

• Reagents and Instruments: This includes genetic research reagents, testing kits, and instrumental solutions designed for a broad spectrum of scientific exploration and diagnostics. Products under this category serve functions ranging from gene expression research to stem cell research, facilitated by respected brand names such as TaKaRa, Clontech, and Cellartis.
• Coronavirus Testing Products: The company has developed a range of products integral to the detection of viruses, especially focusing on in vitro diagnostics that identify the presence of coronavirus, showcasing Takara Bio Inc.’s response to global health emergencies.
• Single-Cell Analysis Systems: These specialized systems enable detailed examination at the single-cell level, a crucial aspect for advancing personalized medicine and understanding cellular functions and diseases at a more granular level.
• Genome-Editing Research Reagents: Takara Bio provides cutting-edge tools for genome editing, facilitating research that could lead to groundbreaking therapeutic strategies and advancements in genetic engineering.
• iPS Cell Research Reagents: The company offers products that support the cultivation and differentiation of induced pluripotent stem (iPS) cells, crucial for regenerative medicine and disease modeling.
• Contract Services for Regenerative Medicine: Through its CDMO business, Takara Bio Inc. delivers comprehensive contract services, from the manufacturing of viral vectors and gene-transduced cells to quality and safety testing and cell banking, thereby accelerating the development of regenerative medicine solutions.
• Gene Analysis and Testing Services: The company also provides a broad spectrum of services for gene analysis and testing, including sequencing, intestinal flora analysis, cancer-associated gene analysis, and custom cell line creation via genome editing. These services help in advancing personalized medicine and understanding the genetic basis of diseases.